Home > Blog > Pfizer Settles Investor Lawsuit Over Celebrex

Drug giant Pfizer has agreed to pay $164 million to settle a shareholder class-action lawsuit over Celebrex, a pain reliever that became the company’s 5th best-selling drug, pulling in $2.5 billion a year.

Pfizer was accused of misrepresenting the drug in clinical trials, making it appear safer than it actually was.

This is not the first litigation Pfizer has had to settle in relation to Celebrex.  In 2008, the company settled its personal injury suits for over $745 million.